Advertisement

Diabetologia

pp 1–10 | Cite as

The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice

  • Chelsea R. Hutch
  • Karen Roelofs
  • April Haller
  • Joyce Sorrell
  • Kyle Leix
  • David D. D’Alessio
  • Robert Augustin
  • Randy J. Seeley
  • Thomas Klein
  • Darleen A. SandovalEmail author
Article

Abstract

Aims/hypothesis

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two peptides that function to promote insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase the bioavailability of both GLP-1 and GIP but the dogma continues to be that it is the increase in GLP-1 that contributes to the improved glucose homeostasis. We have previously demonstrated that pancreatic rather than intestinal GLP-1 is necessary for improvements in glucose homeostasis in mice. Therefore, we hypothesise that a combination of pancreatic GLP-1 and GIP is necessary for the full effect of DPP-4 inhibitors on glucose homeostasis.

Methods

We have genetically engineered mouse lines in which the preproglucagon gene (Gcg) is absent in the entire body (GcgRAΔNull) or is expressed exclusively in the intestine (GcgRAΔVilCre) or pancreas and duodenum (GcgRAΔPDX1Cre). These mice were used to examine oral glucose tolerance and GLP-1 and GIP responses to a DPP-4 inhibitor alone, or in combination with incretin receptor antagonists.

Results

Administration of the DPP-4 inhibitor, linagliptin, improved glucose tolerance in GcgRAΔNull mice and control littermates and in GcgRAΔVilCre and GcgRAΔPDX1Cre mice. The potent GLP-1 receptor antagonist, exendin-[9–39] (Ex9), blunted improvements in glucose tolerance in linagliptin-treated control mice and in GcgRAΔPDX1Cre mice. Ex9 had no effect on glucose tolerance in linagliptin-treated GcgRAΔNull or in GcgRAΔVilCre mice. In addition to GLP-1, linagliptin also increased postprandial plasma levels of GIP to a similar degree in all genotypes. When linagliptin was co-administered with a GIP-antagonising antibody, the impact of linagliptin was partially blunted in wild-type mice and was fully blocked in GcgRAΔNull mice.

Conclusions/interpretation

Taken together, these data suggest that increases in pancreatic GLP-1 and GIP are necessary for the full effect of DPP-4 inhibitors on glucose tolerance.

Keywords

DPP-4 inhibitor GIP GLP-1 Glucose homeostasis Incretin 

Abbreviations

DPP-4

Dipeptidyl peptidase-4

Ex9

Exendin-[9–39]

GcgRAΔNull

Gcg null mouse model

GcgRAΔPDX1Cre

Mouse model with Gcg reactivated in the pancreas

GcgRAΔVilCre

Mouse model with Gcg reactivated in the intestine

GIP

Glucose-dependent insulinotropic polypeptide

GIPrAB

GIP receptor-antagonising antibody

GLP-1

Glucagon-like peptide-1

GLP-1R

GLP-1 receptor

PDX1

Pancreatic duodenal homeobox-1

PDX1Cre

Wild-type littermate of GcgRAΔPDX1Cre

VilCre

Wild-type littermate of GcgRAΔVilCre

Notes

Acknowledgements

We would like to thank J. Magrisso (Department of Surgery, University of Michigan, USA) for his technical assistance.

Contribution statement

KR, JS, KL, RA and AH contributed to data acquisition, data analysis and editing of the manuscript. DD, RJS and TK were responsible for conception and experimental design, interpretation of the data and editing of the manuscript. CRH contributed to all aspects of this manuscript, including data acquisition and analysis and drafting and editing the manuscript. DAS contributed to conception, experimental design and drafting the manuscript, provided final approval of the submitted manuscript and is guarantor of this work.

Funding

This work is supported in part by NIH Awards DK107282 (DAS) and DK093848 (RJS). The investigators also received research support from Boehringer Ingelheim (DAS, RJS), Ethicon Endo-Surgery (DAS, RJS), Sanofi (RJS) and Novo Nordisk A/S (DAS, RJS). The study sponsor was not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; or the decision to submit the report for publication.

Duality of interest

RJS has received research support from Ethicon Endo-Surgery, Novo Nordisk, Sanofi and Janssen. RJS has served on scientific advisory boards for Ethicon Endo-Surgery, Daiichi Sankyo, Janssen, Novartis, Nestle, Takeda, Boehringer Ingelheim, Sanofi and Novo Nordisk and is a paid speaker for Ethicon Endo-Surgery. DAS has received research support from Ethicon Endo-Surgery, Novo Nordisk and Boehringer Ingelheim. All other authors declare no duality of interest associated with this manuscript.

Supplementary material

125_2019_4963_MOESM1_ESM.pdf (313 kb)
ESM (PDF 312 kb)

References

  1. 1.
    Fujioka K, O’Neil PM, Davies M et al (2016) Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity 24(11):2278–2288.  https://doi.org/10.1002/oby.21629 CrossRefPubMedGoogle Scholar
  2. 2.
    Nauck MA, Kind J, Köthe LDLD et al (2016) Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes 65(8):2440–2447.  https://doi.org/10.2337/db16-0107 CrossRefPubMedGoogle Scholar
  3. 3.
    Meier JJ, Nauck MA, Kranz D et al (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53(3):654–662.  https://doi.org/10.2337/diabetes.53.3.654 CrossRefPubMedGoogle Scholar
  4. 4.
    Vilsbøll T, Agersø H, Lauritsen T et al (2006) The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137(3):168–172.  https://doi.org/10.1016/j.regpep.2006.07.007 CrossRefPubMedGoogle Scholar
  5. 5.
    Ali S, Lamont BJ, Charron MJ, Drucker DJ (2011) Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121(5):1917–1929.  https://doi.org/10.1172/JCI43615 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45(8):1111–1119.  https://doi.org/10.1007/s00125-002-0878-6 CrossRefPubMedGoogle Scholar
  7. 7.
    Nauck MA, Heimesaat MM, Orskov C et al (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301–307.  https://doi.org/10.1172/JCI116186 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 1(1-2):8–23.  https://doi.org/10.1111/j.2040-1124.2010.00022.x CrossRefGoogle Scholar
  9. 9.
    Chambers AP, Sorrell JE, Haller A et al (2017) The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab 25(4):927–934.  https://doi.org/10.1016/j.cmet.2017.02.008 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ravn P, Madhurantakam C, Kunze S et al (2013) Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288(27):19760–19772.  https://doi.org/10.1074/jbc.M112.426288 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Thomas L, Eckhardt M, Langkopf E et al (2008) (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325(1):175–182.  https://doi.org/10.1124/jpet.107.135723 CrossRefPubMedGoogle Scholar
  12. 12.
    Fukami A, Seino Y, Ozaki N et al (2013) Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 62(2):510–518.  https://doi.org/10.2337/db12-0294 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yabe D, Seino Y, Seino Y (2018) Incretin concept revised: the origin of the insulinotropic function of glucagon-like peptide-1: the gut, the islets or both? J Diabetes Investig 9(1):21–24.  https://doi.org/10.1111/jdi.12718 CrossRefPubMedGoogle Scholar
  14. 14.
    Piteau S, Olver A, Kim S-J et al (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 362(4):1007–1012.  https://doi.org/10.1016/j.bbrc.2007.08.115 CrossRefPubMedGoogle Scholar
  15. 15.
    Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53(5):1326–1335.  https://doi.org/10.2337/diabetes.53.5.1326 CrossRefPubMedGoogle Scholar
  16. 16.
    Flock G, Baggio LL, Longuet C, Drucker DJ (2007) Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56(12):3006–3013.  https://doi.org/10.2337/db07-0697 CrossRefPubMedGoogle Scholar
  17. 17.
    Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35(6):992–1019.  https://doi.org/10.1210/er.2014-1035 CrossRefPubMedGoogle Scholar
  18. 18.
    Aulinger BA, Bedorf A, Kutscherauer G et al (2014) Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 63(3):1079–1092.  https://doi.org/10.2337/db13-1455 CrossRefPubMedGoogle Scholar
  19. 19.
    Mulvihill EE, Varin EM, Gladanac B et al (2017) Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metab 25(1):152–165.  https://doi.org/10.1016/j.cmet.2016.10.007 CrossRefPubMedGoogle Scholar
  20. 20.
    Waget A, Cabou C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152(8):3018–3029.  https://doi.org/10.1210/en.2011-0286 CrossRefPubMedGoogle Scholar
  21. 21.
    Kawamori D, Shirakawa J, Liew CW et al (2017) GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice. Diabetologia 60(8):1442–1453.  https://doi.org/10.1007/s00125-017-4303-6 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Marchetti P, Lupi R, Bugliani M et al (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55(12):3262–3272.  https://doi.org/10.1007/s00125-012-2716-9 CrossRefPubMedGoogle Scholar
  23. 23.
    Traub S, Meier DT, Schulze F et al (2017) Pancreatic α cell-derived glucagon-related peptides are required for β cell adaptation and glucose homeostasis. Cell Rep 18(13):3192–3203.  https://doi.org/10.1016/j.celrep.2017.03.005 CrossRefPubMedGoogle Scholar
  24. 24.
    Lin HV, Wang J, Wang J et al (2018) GPR142 prompts glucagon-like peptide-1 release from islets to improve β cell function. Mol Metab 11:205–211.  https://doi.org/10.1016/j.molmet.2018.02.008 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Capozzi ME, Svendsen B, Encisco SE et al (2019) β Cell tone is defined by proglucagon peptides through cAMP signaling. JCI Insight 4(5):e126742.  https://doi.org/10.1172/jci.insight.126742 CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Dorrell C, Grompe MT, Pan FC et al (2011) Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol Cell Endocrinol 339(1-2):144–150.  https://doi.org/10.1016/j.mce.2011.04.008 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Poulsen MD, Hansen GH, Dabelsteen E et al (1993) Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J Histochem Cytochem 41(1):81–88.  https://doi.org/10.1177/41.1.8093256 CrossRefPubMedGoogle Scholar
  28. 28.
    Augstein P, Naselli G, Loudovaris T et al (2015) Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. Diabetes Res Clin Pract 110(3):291–300.  https://doi.org/10.1016/j.diabres.2015.10.010 CrossRefPubMedGoogle Scholar
  29. 29.
    Omar BA, Liehua L, Yamada Y et al (2014) Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57(9):1876–1883.  https://doi.org/10.1007/s00125-014-3299-4 CrossRefPubMedGoogle Scholar
  30. 30.
    Shah P, Ardestani A, Dharmadhikari G et al (2013) The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 98(7):E1163–E1172.  https://doi.org/10.1210/jc.2013-1029 CrossRefPubMedGoogle Scholar
  31. 31.
    Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? J Endocrinol 211(1):99–106.  https://doi.org/10.1530/JOE-11-0094 CrossRefPubMedGoogle Scholar
  32. 32.
    Aaboe K, Knop FK, Vilsboll T et al (2009) KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 94(2):603–608.  https://doi.org/10.1210/jc.2008-1731 CrossRefPubMedGoogle Scholar
  33. 33.
    Højberg PV, Vilsbøll T, Rabøl R et al (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52(2):199–207.  https://doi.org/10.1007/s00125-008-1195-5 CrossRefPubMedGoogle Scholar
  34. 34.
    Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180–2193.  https://doi.org/10.1016/S0140-6736(18)32260-8 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Chelsea R. Hutch
    • 1
  • Karen Roelofs
    • 1
  • April Haller
    • 2
  • Joyce Sorrell
    • 2
  • Kyle Leix
    • 1
  • David D. D’Alessio
    • 3
  • Robert Augustin
    • 4
  • Randy J. Seeley
    • 1
  • Thomas Klein
    • 4
  • Darleen A. Sandoval
    • 1
    Email author
  1. 1.Department of SurgeryUniversity of MichiganAnn ArborUSA
  2. 2.Department of Internal Medicine-Endocrinology, Diabetes, and MetabolismUniversity of CincinnatiCincinnatiUSA
  3. 3.Division of Endocrinology, Metabolism, and NutritionDuke University Medical CenterDurhamUSA
  4. 4.Cardiometabolic Diseases Research (Biberach)Boehringer IngelheimIngelheim am RheinGermany

Personalised recommendations